Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative.
Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, Mursaleen L, Schwarzschild MA, Stott SRW, Sulzer D, Svenningsson P, Tanner CM, Carroll C, Simon DK, Brundin P. Wyse RK, et al. Among authors: greenamyre jt. J Parkinsons Dis. 2024 Apr 5. doi: 10.3233/JPD-230363. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38578902 Review.
Neuroprotective actions of a fatty acid nitroalkene in Parkinson's disease.
Di Maio R, Keeney MT, Cechova V, Mortimer A, Sekandari A, Rowart P, Greenamyre JT, Freeman BA, Fazzari M. Di Maio R, et al. Among authors: greenamyre jt. NPJ Parkinsons Dis. 2023 Apr 7;9(1):55. doi: 10.1038/s41531-023-00502-3. NPJ Parkinsons Dis. 2023. PMID: 37029127 Free PMC article.
The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability.
Hallacli E, Kayatekin C, Nazeen S, Wang XH, Sheinkopf Z, Sathyakumar S, Sarkar S, Jiang X, Dong X, Di Maio R, Wang W, Keeney MT, Felsky D, Sandoe J, Vahdatshoar A, Udeshi ND, Mani DR, Carr SA, Lindquist S, De Jager PL, Bartel DP, Myers CL, Greenamyre JT, Feany MB, Sunyaev SR, Chung CY, Khurana V. Hallacli E, et al. Among authors: greenamyre jt. Cell. 2022 Jun 9;185(12):2035-2056.e33. doi: 10.1016/j.cell.2022.05.008. Cell. 2022. PMID: 35688132 Free PMC article.
NADPH oxidase 2 activity in Parkinson's disease.
Keeney MT, Hoffman EK, Farmer K, Bodle CR, Fazzari M, Zharikov A, Castro SL, Hu X, Mortimer A, Kofler JK, Cifuentes-Pagano E, Pagano PJ, Burton EA, Hastings TG, Greenamyre JT, Di Maio R. Keeney MT, et al. Among authors: greenamyre jt. Neurobiol Dis. 2022 Aug;170:105754. doi: 10.1016/j.nbd.2022.105754. Epub 2022 May 13. Neurobiol Dis. 2022. PMID: 35577065 Free PMC article.
LRRK2 and idiopathic Parkinson's disease.
Rocha EM, Keeney MT, Di Maio R, De Miranda BR, Greenamyre JT. Rocha EM, et al. Among authors: greenamyre jt. Trends Neurosci. 2022 Mar;45(3):224-236. doi: 10.1016/j.tins.2021.12.002. Epub 2022 Jan 4. Trends Neurosci. 2022. PMID: 34991886 Free PMC article. Review.
Preventing Parkinson's Disease: An Environmental Agenda.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. De Miranda BR, et al. Among authors: greenamyre jt. J Parkinsons Dis. 2022;12(1):45-68. doi: 10.3233/JPD-212922. J Parkinsons Dis. 2022. PMID: 34719434 Free PMC article. Review.
Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to age-related neurodegeneration.
Buck SA, Steinkellner T, Aslanoglou D, Villeneuve M, Bhatte SH, Childers VC, Rubin SA, De Miranda BR, O'Leary EI, Neureiter EG, Fogle KJ, Palladino MJ, Logan RW, Glausier JR, Fish KN, Lewis DA, Greenamyre JT, McCabe BD, Cheetham CEJ, Hnasko TS, Freyberg Z. Buck SA, et al. Among authors: greenamyre jt. Aging Cell. 2021 May;20(5):e13365. doi: 10.1111/acel.13365. Epub 2021 Apr 28. Aging Cell. 2021. PMID: 33909313 Free PMC article.
212 results